Brokerages Anticipate OptiNose Inc (NASDAQ:OPTN) Will Post Quarterly Sales of $8.56 Million

Wall Street brokerages expect OptiNose Inc (NASDAQ:OPTN) to announce $8.56 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for OptiNose’s earnings. The highest sales estimate is $8.61 million and the lowest is $8.50 million. OptiNose reported sales of $1.90 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 350.5%. The company is expected to issue its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that OptiNose will report full year sales of $32.45 million for the current fiscal year, with estimates ranging from $32.10 million to $32.79 million. For the next fiscal year, analysts expect that the business will post sales of $84.08 million, with estimates ranging from $77.80 million to $90.35 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow OptiNose.

OptiNose (NASDAQ:OPTN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.09. OptiNose had a negative return on equity of 102.10% and a negative net margin of 670.20%. The firm had revenue of $6.68 million for the quarter, compared to analysts’ expectations of $7.74 million.

Several equities analysts recently issued reports on the company. Royal Bank of Canada set a $20.00 price objective on OptiNose and gave the stock a “buy” rating in a research note on Monday, August 12th. ValuEngine upgraded OptiNose from a “hold” rating to a “buy” rating in a research note on Thursday, October 3rd. BMO Capital Markets reduced their price objective on OptiNose from $26.00 to $24.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, Zacks Investment Research lowered OptiNose from a “hold” rating to a “sell” rating in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $21.50.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its position in OptiNose by 223.5% in the second quarter. Royal Bank of Canada now owns 38,174 shares of the company’s stock worth $270,000 after buying an additional 26,374 shares during the period. Susquehanna International Group LLP acquired a new stake in OptiNose in the second quarter worth $77,000. UBS Asset Management Americas Inc. acquired a new stake in OptiNose in the second quarter worth $72,000. Cubist Systematic Strategies LLC acquired a new stake in OptiNose in the second quarter worth $82,000. Finally, Bank of America Corp DE increased its position in OptiNose by 8.1% in the second quarter. Bank of America Corp DE now owns 105,689 shares of the company’s stock worth $748,000 after buying an additional 7,944 shares during the period. 64.98% of the stock is currently owned by hedge funds and other institutional investors.

OPTN traded down $0.27 during trading hours on Wednesday, hitting $7.44. 221,500 shares of the stock were exchanged, compared to its average volume of 191,347. The stock has a 50-day simple moving average of $7.24 and a 200-day simple moving average of $7.50. OptiNose has a 12 month low of $4.44 and a 12 month high of $12.05. The stock has a market cap of $314.91 million, a price-to-earnings ratio of -2.78 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 6.60 and a quick ratio of 6.43.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Recommended Story: Economic Reports

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.